A curated eBook featuring ESMO 2023: eNSCLC-focused studies, findings, and expert opinions.
Nov 30, 2023
Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.
Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.
For a retrospective study involving 607 oncology patients treated from 2014-2019, the potential for predicting patient prognosis and guiding immunotherapy treatment through the analysis of total tumor volume (TTV) and artificial intelligence (AI) tumor heterogeneity from CT scans was investigated.
In early-stage non-small cell lung cancer (NSCLC), the recommended treatment options include targeted and immune therapies.